Exploring Case 2 Ponatinib For T315i Mutated Cml
Exploring Case 2 Ponatinib For T315i Mutated Cml reveals several interesting facts.
- Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the challenges in treating ...
- Rationale for using
- Thihan Padukkavidana, PhD, from Takeda Oncology, discusses post-hoc analysis data on the efficacy and safety of
- Michael Deininger, MD, PhD, University of Utah, Salt Lake City, UT, discusses results from a post hoc analysis of responses to ...
- Hagop Kantarjian, MD, from The University of Texas MD Anderson Cancer Center, discusses data on the efficacy and safety of ...
In-Depth Information on Case 2 Ponatinib For T315i Mutated Cml
Clinical recommendations surrounding the use of Considerations for treating a patient with relapsed The role of molecular testing and biopsy in the assessment of a patient with relapsed At ASH 2014, Dr. Michael Mauro discussed his abstract titled
Michael Deininger, MD, PhD, discusses 4-year outcomes with
Stay tuned for more updates related to Case 2 Ponatinib For T315i Mutated Cml.